Literature DB >> 8701406

Isolation and characterization of canine factor IX.

Y Sugahara1, J Catalfamo, M Brooks, E Hitomi, S P Bajaj, K Kurachi.   

Abstract

Canine plasma factor IX was purified to homogeneity by a combination of barium citrate precipitation and three-step column chromatographies of DEAE sepharose, heparin agarose and a monoclonal antifactor IX antibody-linked agarose. Canine factor IX has an apparent molecular size of 61 kDa, which is slightly smaller than that of human factor IX, as determined by denatured polyacrylamide gel electrophoresis. Its amino acid composition, amino-terminal and carboxyterminal amino acid sequences agreed well with those predicted from the reported cDNA. Unlike purified human factor IX, canine factor IX preparation often showed a discrete smaller molecular species (approximately 50 kDa) which was generated by a specific proteolytic cleavage between Arg310 and Val311. When purified canine factor IX was utilized as a standard for enzyme linked immunosorbent assay, the concentration of canine factor IX in the pooled normal dog plasma was determined to be 5.3 micrograms/ml with 11.2% carbohydrate content (or 4.7 micrograms/ml for its polypeptide chain moiety). Concentration of plasma factor IX antigen was measured in six severely affected, unrelated hemophilia B dogs. Four had factor IX antigen of less than 1% of the normal, and two had undetectable levels. The latter two had gross molecular abnormalities in their factor IX genes. Three obligate carrier females had variable but proportionately reduced factor IX antigen and factor IX coagulant activity levels. These results provide a quantitative method for measuring canine factor IX antigen which is a prerequisite for studying hemostasis and development of gene transfer approaches in the canine model of hemophilia B.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8701406

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony.

Authors:  R W Herzog; V R Arruda; T H Fisher; M S Read; T C Nichols; K A High
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

2.  Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.

Authors:  T C Nichols; H W G Franck; C T Franck; N De Friess; R A Raymer; E P Merricks
Journal:  J Thromb Haemost       Date:  2012-03       Impact factor: 5.824

3.  A Line 1 insertion in the Factor IX gene segregates with mild hemophilia B in dogs.

Authors:  Marjory B Brooks; Weikuan Gu; Jennifer L Barnas; Jharna Ray; Kunal Ray
Journal:  Mamm Genome       Date:  2003-11       Impact factor: 2.957

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.